Distribution agreement for CholBiome®x3

RNS Number : 1183W

OptiBiotix Health PLC

09 December 2019

 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Distribution agreement for CholBiome®_x3 in the Philippines

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd. ("ProBiotix"), has signed an exclusive agreement with CTC Far East Philippines, Inc. ("CTC"), a subsidiary of the CTC Group, for the distribution of ProBiotix's  proprietary formulation CholBiome®x3 in the Philippines.

Under the terms of the agreement, ProBiotix will supply CholBiome®_x3, featuring its cholesterol and blood pressure-reducing probiotic strain Lactobacillus plantarum LP_LDL®, to CTC for its distribution in the Philippines.  Exclusivity is subject to minimum order quantities and a multiyear business plan in an attempt to improve security of income and revenue growth.

"CTC Group (CTC), is the global business network group of the Koen Visser Corporation. CTC is active in Europe, Africa, South and Central America, Caribbean and Asia with head office located in Amsterdam, The Netherlands. CTC Group is a global life science partner-provider of innovative product solutions for food, beverage, personal care products, and health and wellness."

The Philippines is a country with an expanding population of over 100 million and an emerging economy with annual GDP growth rates above 6% sustained over the last 5 years (World Bank). Cardiovascular disease is the leading cause of death in the country, with high blood pressure affecting almost 20% of its population (WHO).

Steve Prescott, CEO of ProBiotix, commented: "We are pleased to announce this agreement with CTC, which will expand ProBiotix's presence in the emerging Asia-Pacific region. CTC was chosen as our partner for CholBiome®_x3  product introduction in the Philippines because of their extensive knowledge of the local market and consistent track record successfully launching new products."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

OptiBiotix Health plc		www.optibiotix.com
Stephen O'Hara, Chief Executive		Contact via Walbrook below
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner		Tel: [phone]
finnCap (Broker)
Geoff Nash/ Scott Mathieson / Kate Bannatyne (Corporate Finance) Camille Gochez (Corporate Broking)		Tel: [phone]
Goetz Partner Securities Limited Brigitte de Lima Walbrook PR Ltd	T [phone] |
Anna Dunphy		Mob: [phone]

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

 

END

 

 

AGRUGGMWPUPBGBQ